TriLink recovery takes root without COVID revenue
- Q2 2026 TriLink revenue grew 12% with zero COVID contribution.
- GMP consumables stood out with 55% year-over-year growth.
- The corporate realignment plan drove a massive margin expansion.
- Cygnus provided steady growth for a fifth consecutive quarter.
- Large manufacturing orders remain lumpy and can cause quarter-to-quarter volatility.
A proven post-COVID turnaround
Maravai provided strong confirmation in Q2 2026 that its turnaround is real. The core TriLink business grew 12% year over year, and GMP consumables surged 55%. Most importantly, this growth happened with absolutely zero revenue from COVID programs. The company also successfully refinanced its debt, pushing maturities to 2032 and halving its debt load.
The restructuring plan implemented in 2025 is yielding serious benefits. As revenue recovered in Q2, the leaner cost structure drove a massive 1,600 basis point expansion in adjusted gross margin. Furthermore, the company is successfully using e-commerce to acquire record numbers of new customers.
The bear case now centers on the timing of large orders rather than structural decline. Contract manufacturing and large GMP orders are program-driven, making quarterly revenue vulnerable to shifts if a customer delays a clinical trial. Additionally, major commercial scale-up for the current pipeline is not expected until 2028 or 2029.
Finn views the situation as materially improved. The complete absence of COVID revenue removes a major overhang, and the margin expansion proves the cost cuts were effective. The main question going forward is whether TriLink can maintain steady growth through seasonally weaker periods without relying on large, lumpy orders.
Tools for drug makers
Maravai sells products used by drug, vaccine, diagnostic, and research customers. The business relies on a land and expand strategy. It seeds future manufacturing demand by winning customers early in their discovery phases, hoping to retain them as they move into commercial production.
Its TriLink unit makes modified nucleic acids, including CleanCap analogs and GMP mRNA. These are building blocks and process inputs for advanced therapy work. Cygnus sells products and services that help biologic drug makers test for impurities, which is critical for drug safety.
Sales are increasingly driven by a highly successful e-commerce platform. This system automates ordering for basic research and discovery customers. In Europe and Asia Pacific, Maravai uses a mix of direct sales and third-party distributors.
The company recently executed a 2025 Corporate Realignment Plan to cut costs. This plan is now flowing through the income statement, providing operating leverage and significantly expanding margins as revenue recovers.
What Maravai sells
mRNA products
This is the largest piece of TriLink, representing roughly 35% of total non-COVID revenue. It includes CleanCap analogs used in mRNA vaccine and therapy production.
GMP consumables
TriLink makes highly modified nucleic acids and GMP mRNA for customers moving into higher-grade clinical production. This segment grew 55% in Q2 2026.
Specialty Chemistry
Making up roughly 20% of revenue, this category includes discovery consumables and highly specialized chemical inputs for research.
CDMO services
Contract manufacturing represents less than 5% of revenue but serves as a strategic capability for customers scaling up their therapies.
GMP-grade enzymes
A newly launched portfolio designed to expand Maravai's single-source capabilities for customers. The company expects to add GMP-grade ModTail later in 2026.
Cygnus impurity testing
Cygnus provides antibody-based products and services that detect impurities in biologic drug manufacturing. It provides stable, recurring, high-margin revenue.
Q1 mix favors TriLink
Segment mix is from the three months ended March 31, 2026. TriLink was about 72.1% of revenue, though Q2 2026 confirmed this core segment is now growing without any COVID contribution.
What could still break
Lumpy manufacturing orders
High impact · High oddsThe CDMO and large GMP orders are inherently lumpy. They depend on specific customer clinical programs. A delay in just one or two customer trials can shift revenue out of a quarter and cause unexpected misses.
Delayed clinical scaling
Medium impact · Medium oddsCommercial programs from the current clinical pipeline are not expected to scale into large revenue drivers until 2028 or 2029. Until then, near-term growth relies heavily on discovery and early clinical phases.
Biotech funding constraints
Medium impact · Medium oddsMaravai sells into drug discovery and development markets. If early-stage biotech customers face tight R&D budgets, demand for early discovery products could weaken again.
Impairment history
High impact · Low oddsMaravai recorded massive goodwill and intangible asset impairments in 2025. While operations are improving, any return to weak demand could trigger further write-downs of remaining assets.
In one breath
What does Maravai LifeSciences do?
Maravai sells life science tools used to develop drugs, vaccines, diagnostics, and biologics. Its biggest unit, TriLink, focuses on mRNA and nucleic acid products, while Cygnus focuses on biologics safety testing.
Is Maravai growing again?
Yes. After a long decline, the company reported 12% revenue growth in its core TriLink segment during Q2 2026, with zero help from COVID-related sales. GMP consumables grew 55%.
What is the biggest risk for MRVI stock?
The biggest risk is the lumpy nature of large commercial manufacturing orders. Because a few large programs drive significant revenue, changes in customer timelines can cause revenue to swing unpredictably from quarter to quarter.
